🇺🇸 FDA
Pipeline program

YTS109 cell

IIT2025030

Phase 1 mab active

Quick answer

YTS109 cell for Systemic Lupus Erythematosus (SLE) is a Phase 1 program (mab) at China SXT Pharmaceuticals with 4 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Systemic Lupus Erythematosus (SLE)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials